Exploratory analysis of biological age measures in a remyelination clinical trial
Authors:
- Christopher E McMurranCMChristopher E McMurran
- Ermelinda de MeoEMErmelinda de Meo
- Nick G CunniffeNCNick G Cunniffe
- J William L BrownJBJ William L Brown
- Ferran PradosFPFerran Prados
- Baris KanberBKBaris Kanber
- James H ColeJCJames H Cole
- Alasdair J ColesACAlasdair J Coles
- Sara HäggSHSara Hägg
- Declan T ChardDCDeclan T Chard
Open Access
- 24 December 2024
- journal article
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 7 (1) , fcaf032
Abstract
Enhancing CNS myelin repair (remyelination) is a promising strategy to prevent neurodegeneration and associated progressive disability in multiple sclerosis. Remyelination becomes inefficient with older chronological age, but the relationship between measures of biological age and remyelination has not been previously described in a clinical cohort. Here, we investigated two measures of biological age amongst participants of the Cambridge Centre for Myelin Repair One trial of bexarotene: MRI brain age (BAMRI) and a blood-based biological age (BABlood). In people with radiologically stable multiple sclerosis (n = 44 of 49 total participants), we found that treatment with bexarotene, along with promoting remyelination, was associated with significant decrease in MRI brain age [−1.98 years, 95% confidence interval (CI) [−3.75, −0.21 years] versus placebo over 6 months, P = 0.034]. Whilst BAMRI increased as expected during the trial in the placebo group (+0.92 years, CI [−0.41, 2.26]), the brain MRIs of participants treated with bexarotene appeared on average 11 months younger at the end compared to the start of the trial (−0.93 years, CI [−2.02, 0.17]). The effect of bexarotene on BAMRI was associated with its remyelinating activity in cortical grey matter lesions (β = 0.25% units (pu)/year, CI [0.03, 0.46], P = 0.023) and brainstem lesions (β = 0.24 pu/year, CI [0.09, 0.39], P = 0.003). We also observed some regional trends that the remyelinating response to bexarotene was linked with measures of biological age at baseline. For example, after adjustment for chronological age, remyelination of brainstem lesions assessed by magnetization transfer ratio was reduced by 0.06 pu for each year increase in BAMRI (CI [0.00, 0.13], P = 0.058) and 0.02 pu for each year increase in BABlood (CI [−0.01, 0.05], P = 0.17). This is, to the best of our knowledge, the first demonstration that MRI brain age can be therapeutically modulated by a drug in people with a neurological disorder. Overall, these findings highlight that beyond chronological age, biological age may also influence the potential for repair and should be considered when developing treatments for multiple sclerosis.Keywords
Funding Information
- Cambridge National Institute for Health and Care Research
- Biomedical Centre and Clinical Research Facility
- United Kingdom Multiple Sclerosis Society
This publication has 33 references indexed in Scilit:
- “Brain age” predicts disability accumulation in multiple sclerosisAnnals of Clinical and Translational Neurology, 2023
- Remyelination in humans due to a retinoid‐X receptor agonist is age‐dependentAnnals of Clinical and Translational Neurology, 2022
- Assessment of brain age in posttraumatic stress disorder: Findings from the ENIGMA PTSD and brain age working groupsBrain and Behavior, 2021
- A toolkit for quantification of biological age from blood chemistry and organ function test data: BioAgeGeroScience, 2021
- Longitudinal Assessment of Multiple Sclerosis with the Brain‐Age ParadigmAnnals of Neurology, 2020
- Telomere Length Is Associated with Disability Progression in Multiple SclerosisAnnals of Neurology, 2019
- Promoting remyelination in multiple sclerosisJournal of Neurology, 2019
- Biological Age PredictorsEBioMedicine, 2017
- Prediction of brain age suggests accelerated atrophy after traumatic brain injuryAnnals of Neurology, 2015
- Multiple imputation by chained equations: what is it and how does it work?International Journal of Methods in Psychiatric Research, 2011